Denali Therapeutics Inc.

NasdaqGS:DNLI 주식 보고서

시가총액: US$3.9b

Denali Therapeutics 관리

관리 기준 확인 4/4

Denali Therapeutics CEO는 Ryan Watts, Aug2015 에 임명되었습니다 의 임기는 9.25 년입니다. 총 연간 보상은 $ 7.88M, 8.5% 로 구성됩니다. 8.5% 급여 및 91.5% 보너스(회사 주식 및 옵션 포함). 는 $ 60.62M 가치에 해당하는 회사 주식의 1.57% 직접 소유합니다. 60.62M. 경영진과 이사회의 평균 재임 기간은 각각 5.8 년과 8.1 년입니다.

주요 정보

Ryan Watts

최고 경영자

US$7.9m

총 보상

CEO 급여 비율8.5%
CEO 임기9.3yrs
CEO 소유권1.6%
경영진 평균 재임 기간5.8yrs
이사회 평균 재임 기간8.1yrs

최근 관리 업데이트

Recent updates

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Aug 20

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Jul 26
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

May 23
Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

May 13

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Apr 17
An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Mar 21
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Mar 07

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Feb 21
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Jan 26
Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Nov 20
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Oct 09
Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Aug 22
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

May 02
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Mar 04
Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

Feb 06
Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Nov 09
These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Denali Therapeutics proposes $250M stock offering; shares down 6% post market

Oct 18

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Oct 12
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122

Oct 10

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Jun 08
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

CEO 보상 분석

Ryan Watts 의 보수는 Denali Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$420m

Mar 31 2024n/an/a

-US$137m

Dec 31 2023US$8mUS$670k

-US$145m

Sep 30 2023n/an/a

-US$124m

Jun 30 2023n/an/a

-US$128m

Mar 31 2023n/an/a

-US$371m

Dec 31 2022US$9mUS$645k

-US$326m

Sep 30 2022n/an/a

-US$303m

Jun 30 2022n/an/a

-US$284m

Mar 31 2022n/an/a

-US$286m

Dec 31 2021US$13mUS$610k

-US$291m

Sep 30 2021n/an/a

US$30m

Jun 30 2021n/an/a

US$56m

Mar 31 2021n/an/a

US$58m

Dec 31 2020US$9mUS$589k

US$71m

Sep 30 2020n/an/a

-US$228m

Jun 30 2020n/an/a

-US$216m

Mar 31 2020n/an/a

-US$215m

Dec 31 2019US$5mUS$567k

-US$198m

Sep 30 2019n/an/a

-US$66m

Jun 30 2019n/an/a

-US$55m

Mar 31 2019n/an/a

-US$52m

Dec 31 2018US$6mUS$545k

-US$36m

Sep 30 2018n/an/a

-US$137m

Jun 30 2018n/an/a

-US$123m

Mar 31 2018n/an/a

-US$91m

Dec 31 2017US$1mUS$481k

-US$88m

보상 대 시장: Ryan 의 총 보상 ($USD 7.88M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 6.66M ).

보상과 수익: Ryan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Ryan Watts (48 yo)

9.3yrs

테뉴어

US$7,879,267

보상

Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...


리더십 팀

이름위치테뉴어보상소유권
Ryan Watts
Co-Founder9.3yrsUS$7.88m1.57%
$ 60.6m
Alexander Schuth
Co-Founder9.7yrsUS$4.17m0.41%
$ 15.8m
Marc Tessier-Lavigne
Co-Founder & Independent Directorno dataUS$431.93k1.47%
$ 57.1m
Carole Ho
Chief Medical Officer & Head of Development9.4yrsUS$4.17m0.15%
$ 5.6m
Tyler Nielsen
Senior Vice President of Corporate Financeno data데이터 없음데이터 없음
Dana Andersen
Chief Technical and Manufacturing Officer6.3yrs데이터 없음데이터 없음
Joe Lewcock
Chief Scientific Officer4.3yrs데이터 없음데이터 없음
Laura Hansen
Vice President of Investor Relations4.8yrs데이터 없음데이터 없음
Chris Walsh
General Counsel5.8yrs데이터 없음데이터 없음
Mark Rowen
Vice President of Corporate Development1.8yrs데이터 없음데이터 없음
Cindy Dunkle
Chief People Officerno data데이터 없음데이터 없음
Katie Peng
Chief Commercial Officer3.2yrs데이터 없음데이터 없음

5.8yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: DNLI 의 관리팀은 노련하고 경험 (평균 재직 기간 5.8 년)입니다.


이사회 구성원

이름위치테뉴어보상소유권
Ryan Watts
Co-Founder9.7yrsUS$7.88m1.57%
$ 60.6m
Marc Tessier-Lavigne
Co-Founder & Independent Director9.7yrsUS$431.93k1.47%
$ 57.1m
Vicki Sato
Independent Chairperson9.6yrsUS$459.43k0.076%
$ 3.0m
Jay Flatley
Independent Director9.6yrsUS$444.43k0.24%
$ 9.2m
Eric Reiman
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
David Schenkein
Independent Director9.6yrsUS$439.43k0.051%
$ 2.0m
David Holtzman
Member of Scientific Advisory Board4yrs데이터 없음데이터 없음
Peter Klein
Independent Director6.7yrsUS$439.43k0.011%
$ 420.2k
Jennifer Cook
Independent Director6yrsUS$429.43k0.0098%
$ 380.7k
Steve Krognes
Director2.5yrsUS$419.43k0.58%
$ 22.4m
Scott Biller
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Stacie Weninger
Member of Scientific Advisory Board3.8yrs데이터 없음데이터 없음

8.1yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: DNLI 의 이사회경험(평균 재직 기간 8.1 년)으로 간주됩니다.